{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:04:17Z","timestamp":1772028257388,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To investigate whether miR-203a-3p can regulate the biological behaviors of ovarian cancer cells by targeting\n                      <jats:italic>ATM<\/jats:italic>\n                      to affect the Akt\/GSK-3\u03b2\/Snail signaling pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The expression levels of miR-203a-3p and ATM were detected by qRT-PCR, immunohistochemical staining and Western blotting in ovarian cancer tissues and adjacent normal tissues obtained from 152 subjects. A dual-luciferase reporter gene assay was performed to verify the relationship between miR-203a-3p and ATM. Human ovarian cancer cell lines (A2780 and SKOV3) were used to generate the Blank, miR-NC, miR-203a-3p mimic, Control siRNA, ATM siRNA, and miR-203a-3p inhibitor + ATM siRNA groups. The biological behaviors of ovarian cancer cells were evaluated by CCK-8, wound healing, and Transwell invasion assays, annexin V-FITC\/PI staining and flow cytometry. The levels of Akt\/GSK-3\u03b2\/Snail pathway-related proteins were assessed by Western blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ovarian cancer tissues showed lower miR-203a-3p levels and higher ATM levels than adjacent normal tissues, both of which were associated with the FIGO stage, grade and prognosis of ovarian cancer. As confirmed by a dual-luciferase reporter gene assay, miR-203a-3p could target\n                      <jats:italic>ATM<\/jats:italic>\n                      . Furthermore, the miR-203a-3p mimic had multiple effects, including the inhibition of the proliferation, invasion and migration of A2780 and SKOV3 cells, the promotion of cell apoptosis, the arrest of the cell cycle at the G1 phase, and the blockage of the Akt\/GSK-3\u03b2\/Snail signaling pathway. ATM siRNA had similar effects on the biological behaviors of ovarian cancer cells, and these effects could be reversed by a miR-203a-3p inhibitor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>miR-203a-3p was capable of hindering proliferation, migration, and invasion and facilitating the apoptosis of ovarian cancer cells through its modulation of the Akt\/GSK-3\u03b2\/Snail signaling pathway by targeting ATM, and therefore it could serve as a potential therapeutic option for ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-019-0532-2","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T12:02:42Z","timestamp":1562328162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["RETRACTED ARTICLE: MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt\/GSK-3\u03b2\/Snail signaling pathway by targeting ATM"],"prefix":"10.1186","volume":"12","author":[{"given":"Hong-Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Lian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Zhong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Tang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"532_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3892\/ol.2016.4805","volume":"12","author":"A Agostini","year":"2016","unstructured":"Agostini A, Panagopoulos I, Davidson B, Trope CG, Heim S, Micci F. A novel truncated form of HMGA2 in tumors of the ovaries. Oncol Lett. 2016;12:1559\u201363.","journal-title":"Oncol Lett"},{"key":"532_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237\u201349.","journal-title":"Virchows Arch"},{"key":"532_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/sj.bjc.6602041","volume":"91","author":"X Ni","year":"2004","unstructured":"Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW. Characterisation of human kallikrein 6\/protease M expression in ovarian cancer. Br J Cancer. 2004;91:725\u201331.","journal-title":"Br J Cancer"},{"key":"532_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fpubh.2016.00146","volume":"4","author":"Z Teng","year":"2016","unstructured":"Teng Z, Han R, Huang X, Zhou J, Yang J, Luo P, Wu M. Increase of incidence and mortality of ovarian Cancer during 2003-2012 in Jiangsu Province, China. Front Public Health. 2016;4:146.","journal-title":"Front Public Health"},{"key":"532_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1161\/CIRCGENETICS.109.934281","volume":"3","author":"KD Wilson","year":"2010","unstructured":"Wilson KD, Hu S, Venkatasubrahmanyam S, Fu JD, Sun N, Abilez OJ, Baugh JJ, Jia F, Ghosh Z, Li RA, Butte AJ, Wu JC. Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet. 2010;3:426\u201335.","journal-title":"Circ Cardiovasc Genet"},{"key":"532_CR6","doi-asserted-by":"publisher","first-page":"e77853","DOI":"10.1371\/journal.pone.0077853","volume":"8","author":"H Zheng","year":"2013","unstructured":"Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013;8:e77853.","journal-title":"PLoS One"},{"key":"532_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/bmm.14.108","volume":"9","author":"AB Nagaraj","year":"2015","unstructured":"Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015;9:241\u201357.","journal-title":"Biomark Med"},{"key":"532_CR8","doi-asserted-by":"publisher","first-page":"10119","DOI":"10.1038\/s41598-018-27583-y","volume":"8","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhao Z, Yang Y, Luo M, Zhang M, Wang X, Liu L, Hou N, Guo Q, Song T, Guo B, Huang C. MiR-99b-5p and miR-203a-3p function as tumor suppressors by targeting IGF-1R in gastric Cancer. Sci Rep. 2018;8:10119.","journal-title":"Sci Rep"},{"key":"532_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496\u2013506.","journal-title":"Cancer Cell"},{"key":"532_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.5114\/aoms.2018.73975","volume":"14","author":"M Yang","year":"2018","unstructured":"Yang M, Zhang L, Wang X, Zhou Y, Wu S. Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation. Arch Med Sci. 2018;14:1333\u20139.","journal-title":"Arch Med Sci"},{"issue":"02","key":"532_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4149\/neo_2018_180512N312","volume":"66","author":"X. Y. Na","year":"2019","unstructured":"Na XY, Shang XS, Zhao Y, Ren PP, Hu XQ. MiR-203a functions as a tumor suppressor in bladder cancer by targeting SIX4. Neoplasma. 2018;66:211-21.","journal-title":"Neoplasma"},{"key":"532_CR12","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3892\/or.2016.4913","volume":"36","author":"BC Gomes","year":"2016","unstructured":"Gomes BC, Martins M, Lopes P, Morujao I, Oliveira M, Araujo A, Rueff J, Rodrigues AS. Prognostic value of microRNA-203a expression in breast cancer. Oncol Rep. 2016;36:1748\u201356.","journal-title":"Oncol Rep"},{"key":"532_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/2211-5463.12248","volume":"7","author":"W Huo","year":"2017","unstructured":"Huo W, Du M, Pan X, Zhu X, Gao Y, Li Z. miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open Bio. 2017;7:1085\u201391.","journal-title":"FEBS Open Bio"},{"key":"532_CR14","doi-asserted-by":"publisher","first-page":"67288","DOI":"10.18632\/oncotarget.11691","volume":"7","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Zhou Y, Yang H, Li L, Deng X, Cheng C, Xie Y, Luo X, Fang W, Liu Z. A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma. Oncotarget. 2016;7:67288\u2013301.","journal-title":"Oncotarget"},{"key":"532_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtbi.2009.07.022","volume":"261","author":"Y Pei","year":"2009","unstructured":"Pei Y, Wang X, Zhang X. Predicting the fate of microRNA target genes based on sequence features. J Theor Biol. 2009;261:17\u201322.","journal-title":"J Theor Biol"},{"key":"532_CR16","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/j.ejca.2015.06.029","volume":"51","author":"TM Shieh","year":"2015","unstructured":"Shieh TM, Huang YT, Yu CC, Hsia SM, Shih YH, Wang TH. P0028 Isoliquiritigenin causes DNA damage and inhibits ATM expression in oral squamous cell carcinoma. Eur J Cancer. 2015;51:e8\u20139.","journal-title":"Eur J Cancer"},{"key":"532_CR17","doi-asserted-by":"publisher","first-page":"112980","DOI":"10.18632\/oncotarget.22945","volume":"8","author":"CH Yang","year":"2017","unstructured":"Yang CH, Wang Y, Sims M, Cai C, He P, Hacker H, Yue J, Cheng J, Boop FA, Pfeffer LM. MicroRNA203a suppresses glioma tumorigenesis through an ATM-dependent interferon response pathway. Oncotarget. 2017;8:112980\u201391.","journal-title":"Oncotarget"},{"key":"532_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1748-717X-1-35","volume":"1","author":"AR Filippi","year":"2006","unstructured":"Filippi AR, Franco P, Galliano M, Ricardi U. Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiat Oncol. 2006;1:35.","journal-title":"Radiat Oncol"},{"key":"532_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbacli.2014.08.001","volume":"2","author":"TM Abdel-Fatah","year":"2014","unstructured":"Abdel-Fatah TM, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin. 2014;2:10\u20137.","journal-title":"BBA Clin"},{"key":"532_CR20","doi-asserted-by":"publisher","first-page":"29359","DOI":"10.18632\/oncotarget.8833","volume":"7","author":"S Yin","year":"2016","unstructured":"Yin S, Wang P, Yang L, Liu Y, Wang Y, Liu M, Qi Z, Meng J, Shi TY, Yang G, Zang R. Wip1 suppresses ovarian cancer metastasis through the ATM\/AKT\/snail mediated signaling. Oncotarget. 2016;7:29359\u201370.","journal-title":"Oncotarget"},{"key":"532_CR21","first-page":"839","volume":"290","author":"F Zeppernick","year":"2014","unstructured":"Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch GynecolObstet. 2014;290:839\u201342.","journal-title":"Arch GynecolObstet"},{"key":"532_CR22","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2741\/3364","volume":"14","author":"DG Rosen","year":"2009","unstructured":"Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. Ovarian cancer: pathology, biology, and disease models. Front Biosci (Landmark Ed). 2009;14:2089\u2013102.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"532_CR23","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1371\/journal.pone.0000610","volume":"2","author":"E Sonkoly","year":"2007","unstructured":"Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A, Stahle M, Pivarcsi A. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2007;2:e610.","journal-title":"PLoS One"},{"key":"532_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.urolonc.2007.01.019","volume":"25","author":"F Gottardo","year":"2007","unstructured":"Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25:387\u201392.","journal-title":"Urol Oncol"},{"key":"532_CR25","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1947601911425832","volume":"2","author":"P Ru","year":"2011","unstructured":"Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast Cancer cells and enhances cisplatin Chemosensitivity. Genes Cancer. 2011;2:720\u20137.","journal-title":"Genes Cancer"},{"key":"532_CR26","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3892\/ol.2015.3080","volume":"9","author":"T Chen","year":"2015","unstructured":"Chen T, Xu C, Chen J, Ding C, Xu Z, Li C, Zhao J. MicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancer. Oncol Lett. 2015;9:2639\u201346.","journal-title":"Oncol Lett"},{"key":"532_CR27","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.18632\/oncotarget.1928","volume":"5","author":"A Hailer","year":"2014","unstructured":"Hailer A, Grunewald TG, Orth M, Reiss C, Kneitz B, Spahn M, Butt E. Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration. Oncotarget. 2014;5:4144\u201353.","journal-title":"Oncotarget"},{"key":"532_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/0008-5472.CAN-14-1026","volume":"75","author":"H Taipaleenmaki","year":"2015","unstructured":"Taipaleenmaki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, Hesse E, Stein GS, LianJB. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast Cancer and metastatic bone disease. Cancer Res. 2015;75:1433\u201344.","journal-title":"Cancer Res"},{"key":"532_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s10120-015-0521-0","volume":"19","author":"H Imaoka","year":"2016","unstructured":"Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y, Kusunoki M. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 2016;19:744\u201353.","journal-title":"Gastric Cancer"},{"key":"532_CR30","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1007\/s13277-015-4432-9","volume":"37","author":"Y Liu","year":"2016","unstructured":"Liu Y, Dong Z, Liang J, Guo Y, Guo X, Shen S, Kuang G, Guo W. Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development. Tumour Biol. 2016;37:5621\u201332.","journal-title":"Tumour Biol"},{"key":"532_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.bbrc.2015.07.107","volume":"464","author":"D Liu","year":"2015","unstructured":"Liu D, Wu J, Liu M, Yin H, He J, Zhang B. Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2015;464:1215\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"532_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/07357907.2016.1242010","volume":"34","author":"W Liu","year":"2016","unstructured":"Liu W, Dong Z, Liang J, Guo X, Guo Y, Shen S, Kuang G, Guo W. Downregulation of potential tumor suppressor miR-203a by promoter methylation contributes to the invasiveness of gastric cardia adenocarcinoma. Cancer Investig. 2016;34:506\u201316.","journal-title":"Cancer Investig"},{"key":"532_CR33","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","volume":"37","author":"T Shibuta","year":"2013","unstructured":"Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M, Umemura T. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res. 2013;37:1278\u201386.","journal-title":"Leuk Res"},{"key":"532_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ccell.2016.03.013","volume":"29","author":"MJ Bueno","year":"2016","unstructured":"Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. Cancer Cell. 2016;29:607\u20138.","journal-title":"Cancer Cell"},{"key":"532_CR35","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3892\/ol.2016.4449","volume":"11","author":"M Hao","year":"2016","unstructured":"Hao M, Zhao W, Zhang L, Wang H, Yang X. Low folate levels are associated with methylation-mediated transcriptional repression of miR-203 and miR-375 during cervical carcinogenesis. Oncol Lett. 2016;11:3863\u20139.","journal-title":"Oncol Lett"},{"key":"532_CR36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1134\/S0026893318050102","volume":"52","author":"VI Loginov","year":"2018","unstructured":"Loginov VI, Burdennyy AM, Filippova EA, Pronina IV, Kazubskaya TP, Kushlinsky DN, Ermilova VD, Rykov SV, Khodyrev DS, Braga EA. Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 genes associated with ovarian Cancer development and metastasis. Mol Biol (Mosk). 2018;52:801\u20139.","journal-title":"Mol Biol (Mosk)"},{"key":"532_CR37","doi-asserted-by":"publisher","first-page":"659365","DOI":"10.1155\/2012\/659365","volume":"2012","author":"N Okumura","year":"2012","unstructured":"Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, Iseki S, Matsuda S. Against lung Cancer cells: to be, or not to be, that is the problem. Lung Cancer Int. 2012;2012:659365.","journal-title":"Lung Cancer Int"},{"key":"532_CR38","first-page":"193","volume":"32","author":"M Wang","year":"2017","unstructured":"Wang M, Liu G, Shan GP, Wang BB. In vivo and in vitro effects of ATM\/ATR signaling pathway on proliferation, apoptosis, and Radiosensitivity of nasopharyngeal carcinoma cells. Cancer BiotherRadiopharm. 2017;32:193\u2013203.","journal-title":"Cancer BiotherRadiopharm"},{"key":"532_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/1535-7163.MCT-08-1189","volume":"9","author":"Y Li","year":"2010","unstructured":"Li Y, Yang DQ. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther. 2010;9:113\u201325.","journal-title":"Mol Cancer Ther"},{"key":"532_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2016.12.040","volume":"390","author":"R Liu","year":"2017","unstructured":"Liu R, Tang J, Ding C, Liang W, Zhang L, Chen T, Xiong Y, Dai X, Li W, Xu Y, Hu J, Lu L, Liao W, Lu X. The depletion of ATM inhibits colon cancer proliferation and migration via B56gamma2-mediated Chk1\/p53\/CD44 cascades. Cancer Lett. 2017;390:48\u201357.","journal-title":"Cancer Lett"},{"key":"532_CR41","first-page":"7045","volume":"17","author":"L Zhang","year":"2018","unstructured":"Zhang L, Xu LJ, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR, Shan YX. ATMJAKPDL1 signaling pathway inhibition decreases EMT and metastasis of androgenindependent prostate cancer. Mol Med Rep. 2018;17:7045\u201354.","journal-title":"Mol Med Rep"},{"key":"532_CR42","doi-asserted-by":"publisher","first-page":"6886","DOI":"10.1038\/ncomms7886","volume":"6","author":"V Stagni","year":"2015","unstructured":"Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, Falcioni R, Giaccari D, Di Carlo S, Sperati F, Cencioni MT, Barila D. ATM kinase sustains HER2 tumorigenicity in breast cancer. Nat Commun. 2015;6:6886.","journal-title":"Nat Commun"},{"key":"532_CR43","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","volume":"8","author":"SE Golding","year":"2009","unstructured":"Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, O'Connor MJ, Povirk LF, van Meter T, Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8:2894\u2013902.","journal-title":"Mol Cancer Ther"},{"key":"532_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2011.12.043","volume":"319","author":"S Fujimaki","year":"2012","unstructured":"Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, Yamagiwa S, Yano M, Ohkoshi S, Aoyagi Y. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett. 2012;319:98\u2013108.","journal-title":"Cancer Lett"},{"key":"532_CR45","doi-asserted-by":"publisher","first-page":"5874127","DOI":"10.1155\/2016\/5874127","volume":"2016","author":"LL Lu","year":"2016","unstructured":"Lu LL, Chen XH, Zhang G, Liu ZC, Wu N, Wang H, Qi YF, Wang HS, Cai SH, Du J. CCL21 facilitates Chemoresistance and Cancer stem cell-like properties of colorectal Cancer cells through AKT\/GSK-3beta\/snail signals. Oxidative Med Cell Longev. 2016;2016:5874127.","journal-title":"Oxidative Med Cell Longev"},{"key":"532_CR46","doi-asserted-by":"publisher","first-page":"82303","DOI":"10.18632\/oncotarget.19398","volume":"8","author":"S Wang","year":"2017","unstructured":"Wang S, Wang X, Li J, Meng S, Liang Z, Xu X, Zhu Y, Li S, Wu J, Xu M, Ji A, Lin Y, Liu B, Zheng X, Xie B, Xie L. c-Met, CREB1 and EGFR are involved in miR-493-5p inhibition of EMT via AKT\/GSK-3beta\/snail signaling in prostate cancer. Oncotarget. 2017;8:82303\u201313.","journal-title":"Oncotarget"},{"key":"532_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41419-018-0262-1","volume":"9","author":"Y Lan","year":"2018","unstructured":"Lan Y, Han J, Wang Y, Wang J, Yang G, Li K, Song R, Zheng T, Liang Y, Pan S, Liu X, Zhu M, Liu Y, Meng F, Mohsin M, Cui Y, Zhang B, Subash S, Liu L. STK17B promotes carcinogenesis and metastasis via AKT\/GSK-3beta\/snail signaling in hepatocellular carcinoma. Cell Death Dis. 2018;9:236.","journal-title":"Cell Death Dis"},{"key":"532_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/jmcb\/mjs048","volume":"4","author":"M Sun","year":"2012","unstructured":"Sun M, Guo X, Qian X, Wang H, Yang C, Brinkman KL, Serrano-Gonzalez M, Jope RS, Zhou B, Engler DA, Zhan M, Wong ST, Fu L, Xu B. Activation of the ATM-snail pathway promotes breast cancer metastasis. J Mol Cell Biol. 2012;4:304\u201315.","journal-title":"J Mol Cell Biol"}],"updated-by":[{"DOI":"10.1186\/s13048-025-01902-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000}}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-019-0532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:21:46Z","timestamp":1763616106000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0532-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"6 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13048-025-01902-0","URL":"https:\/\/doi.org\/10.1186\/s13048-025-01902-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the patients in this study signed the informed consent form prior to the study, and all experiments gained the approval of the Ethics Committee for Clinical Experiments at Linyi Central Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}